FindTrial
Sign In

A clinical trial to study the cognitive impairment in persons with drug resistant epilepsy on anti seizure medications

Determination of cognitive impairment in pharmacoresistant epilepsy patients on Anti-seizure drugs (ASDs) A prospective, observational study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/066894
Enrollment
140
Registered
2024-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G409- Epilepsy, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

AIIMS, New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Person diagnosed with epilepsy on the basis of ILAE criteria. 2. Subject willing to participate and able to provide written informed consent. 3. Subject with basic understanding of Hindi or English.

Exclusion criteria

Exclusion criteria: 1. Patients who are unwilling to participate and do not provide written informed consent. 2. Alcohol consumption. 3. Pregnant and lactating women. 4. History of other chronic communicable/noncommunicable, medical illness.

Design outcomes

Primary

MeasureTime frame
1. MoCA Score 2. ACE-III Score 3. Serum biomarkers for BDNF, Homocysteine, Pyridoxine.Timepoint: Baseline—

Secondary

MeasureTime frame
To assess domainwise cognitive impairment.Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Manish Sharma

All India Institute of Medical Sciences

jatinderkatyal.aiims@gmail.com01126593282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026